The α 1A-adrenoceptor gene is required for the α 1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate

British Journal of Pharmacology

Volumn 155, Issue 1, 2008, Pages 103-109

  Gray, K T ^a   Short, J L ^a   Ventura, S ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Benign prostatic hyperplasia; BPH; Nerve stimulation; Noradrenaline; Prazosin; Smooth muscle; Tamsulosin

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1L ADRENERGIC RECEPTOR; NORADRENALIN; PRAZOSIN; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR ALPHA(1A); ADRENERGIC RECEPTOR ALPHA(1L); ALPHA 1 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROSTIMULATION; GENE DELETION; GENE DISRUPTION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; MALE; MOUSE; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE; WILD TYPE; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; INNERVATION; METABOLISM; MOUSE MUTANT; MUSCLE CONTRACTION; PHENOTYPE;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ELECTRIC STIMULATION; GENOTYPE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE CONTRACTION; NOREPINEPHRINE; PHENOTYPE; PRAZOSIN; PROSTATE; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 50249084421     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.245     Document Type: Article

References (41)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl 2): S1-S209.
2. Buljubasich R, Ventura S (2004). Adenosine 5′-triphosphate and noradrenaline are excitatory cotransmitters to the fibromuscular stroma of the guinea pig prostate gland. Eur J Pharmacol 499: 335-344.
3. Bylund DB, Bond RA, Clarke DE, Eikenburg DC, Hieble JP, Langer SZ et al. (1998). Adrenoceptors. In: Girdlestone D (ed). The IUPHAR Compendium of Receptor Characterization and Classification. IUPHAR Media: London, pp 58-74.
4. 1L-adrenoceptor pharmacology in functional studies. Eur J Pharmacol 370: 337-343.
5. Eckhardt MD, van Venrooij GE, Boon TA (2001a). Interactions between prostate volume, filling cystometric estimated parameters, and data from pressure-flow studies in 565 men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Neurourol Urodyn 20: 579-590.
6. Eckhardt MD, van Venrooij GE, Boon TA (2001b). Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 57: 695-700.
7. Eckhardt MD, van Venrooij GE, Boon TA (2001c). Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia. Urology 58: 966-971.
8. Flannery MT, Ramsdell J, Ranhosky A, Davidai G, Ruoff G (2006). Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting. Curr Med Res Opin 22: 721-730.
9. Flavahan NA, Vanhoutte PM (1986). Alpha-1 and alpha-2 adrenoceptor: response coupling in canine saphenous and femoral veins. J Pharmacol Exp Ther 238: 131-138.
10. 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol 49: 209-215.
11. 1- adrenoceptor classification. Br J Pharmacol 121: 1127-1135.
12. Gray KT, Ventura S (2005). Evaluation of the mouse prostate as a suitable model for the study of human prostate function. J Pharmacol Toxicol Methods 51: 41-50.
13. Gray KT, Ventura S (2006). Alpha1L-adrenoceptors mediate contractions of the isolated mouse prostate. Eur J Pharmacol 540: 155-161.
14. Hasan M, Parveen F, Shamsuzzaman AK, Kibria MD (2007). Comparison of efficacy between tamsulosin and finasteride on symptomatic benign prostatic hyperplasia. Mymensingh Med J 16: 154-159.
15. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ et al. (1995). International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 47: 267-270.
16. Hiraoka Y, Ohmura T, Oshita M, Watanabe Y, Morikawa K, Nagata O et al. (1999). Binding and functional characterization of alpha1-adrenoceptor subtypes in the rat prostate. Eur J Pharmacol 366: 119-126.
17. Israilova M, Tanaka T, Suzuki F, Morishima S, Muramatsu I (2004). Pharmacological characterization and cross talk of alpha1a- and alpha1b-adrenoceptors coexpressed in human embryonic kidney 293 cells. J Pharmacol Exp Ther 309: 259-266.
18. Kyprianou N, Chon J, Benning CM (2000). Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. Prostate Suppl 9: 42-46.
19. Marinese D, Patel R, Walden PD (2003). Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 54: 230-237.
20. McNeal JE (1978). Origin and evolution of benign prostatic enlargement. Invest Urol 15: 340-345.
21. 3H]prazosin binding. Mol Pharmacol 29: 321-330.
22. Muramatsu I, Oshita M, Ohmura T, Kigoshi S, Akino H, Gobara M et al. (1994). Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br J Urol 74: 572-578.
23. Nasu K, Moriyama N, Kawabe K, Tsujimoto G, Murai M, Tanaka T et al. (1996). Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 119: 797-803.
24. Nelson CP, Challiss RA (2007). 'Phenotypic' pharmacology: the influence of cellular environment on G protein-coupled receptor antagonist and inverse agonist pharmacology. Biochem Pharmacol 73: 737-751.
25. 1D- adrenoceptor subtypes. Br J Pharmacol 120: 231-238.
26. 1L-Adrenoceptors mediate noradrenaline-induced contractions of the guinea-pig prostate stroma. Eur J Pharmacol 384: 25-30.
27. Piao H, Taniguchi T, Nakamura S, Zhu J, Suzuki F, Mikami D et al. (2000). Cloning of rabbit alpha(1b)-adrenoceptor and pharmacological comparison of alpha(1a)-, alpha(1b)- and alpha(1d)-adrenoceptors in rabbit. Eur J Pharmacol 396: 9-17.
28. 1L-adrenoceptor. Mol Pharmacol 66: 228-239.
29. Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, Rizzi CA (2003). A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 6: 315-323.
30. Rokosh DG, Simpson PC (2002). Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA 99: 9474-9479.
31. Ruffolo Jr RR, Hieble JP (1999). Adrenoceptor pharmacology: urogenital applications. Eur Urol 36 (Suppl 1): 17-22.
32. 1d-adrenoceptor. Biochim Biophys Acta - Biomembr 1323: 6-11.
33. 1a-adrenoceptor in rabbit. Br J Pharmacol 129: 1569-1576.
34. Suzuki H, Yano M, Awa Y, Nakatsu H, Egoshi K, Mikami K et al. (2006). Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey. Int J Urol 13: 1202-1206.
35. Ventura S, Dewalagama RK, Lau LC (2003). Adenosine 5′-triphosphate (ATP) is an excitatory cotransmitter with noradrenaline to the smooth muscle of the rat prostate gland. Br J Pharmacol 138: 1277-1284.
36. 1D- adrenoceptors in hyperplastic and nonhyperplastic human prostate. J Urol 161: 635-640.
37. Walden PD, Ittmann M, Monaco ME, Lepor H (1998). Endothelin-1 production and agonist activities in cultured prostate-derived cells: implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. Prostate 34: 241-250.
38. Watanabe H, Shima M, Kojima M, Ohe H (1988). Dynamic study of nervous control on prostatic contraction and fluid excretion in the dog. J Urol 140: 1567-1570.
39. Yamada S, Okura T, Kimura R (2001). In vivo demonstration of alpha(1A)-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther 296: 160-167.
40. Yang XP, Chiba S (2001). Existence of different alpha(1)-adrenoceptor subtypes in junctional and extrajunctional neurovascular regions in canine splenic arteries. Br J Pharmacol 132: 1852-1858.
41. Zacharia J, Hillier C, Macdonald A (2004). Pharmacological characterization of alpha1-adrenoceptors in mouse isolated femoral small arteries. Eur J Pharmacol 503: 155-163.